Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2014

Open Access 01-12-2014 | Original investigation

Impaired relaxation despite upregulated calcium-handling protein atrial myocardium from type 2 diabetic patients with preserved ejection fraction

Authors: Regis R Lamberts, Shivanjali J Lingam, Heng-Yu Wang, Ilse AE Bollen, Gillian Hughes, Ivor F Galvin, Richard W Bunton, Andrew Bahn, Rajesh Katare, J Chris Baldi, Michael JA Williams, Pankaj Saxena, Sean Coffey, Peter P Jones

Published in: Cardiovascular Diabetology | Issue 1/2014

Login to get access

Abstract

Background

Diastolic dysfunction is a key factor in the development and pathology of cardiac dysfunction in diabetes, however the exact underlying mechanism remains unknown, especially in humans. We aimed to measure contraction, relaxation, expression of calcium-handling proteins and fibrosis in myocardium of diabetic patients with preserved systolic function.

Methods

Right atrial appendages from patients with type 2 diabetes mellitus (DM, n = 20) and non-diabetic patients (non-DM, n = 36), all with preserved ejection fraction and undergoing coronary artery bypass grafting (CABG), were collected. From appendages, small cardiac muscles, trabeculae, were isolated to measure basal and β-adrenergic stimulated myocardial function. Expression levels of calcium-handling proteins, sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) and phospholamban (PLB), and of β1-adrenoreceptors were determined in tissue samples by Western blot. Collagen deposition was determined by picro-sirius red staining.

Results

In trabeculae from diabetic samples, contractile function was preserved, but relaxation was prolonged (Tau: 74 ± 13 ms vs. 93 ± 16 ms, non-DM vs. DM, p = 0.03). The expression of SERCA2a was increased in diabetic myocardial tissue (0.75 ± 0.09 vs. 1.23 ± 0.15, non-DM vs. DM, p = 0.007), whereas its endogenous inhibitor PLB was reduced (2.21 ± 0.45 vs. 0.42 ± 0.11, non-DM vs. DM, p = 0.01). Collagen deposition was increased in diabetic samples. Moreover, trabeculae from diabetic patients were unresponsive to β-adrenergic stimulation, despite no change in β1-adrenoreceptor expression levels.

Conclusions

Human type 2 diabetic atrial myocardium showed increased fibrosis without systolic dysfunction but with impaired relaxation, especially during β-adrenergic challenge. Interestingly, changes in calcium-handling protein expression suggests accelerated active calcium re-uptake, thus improved relaxation, indicating a compensatory calcium-handling mechanism in diabetes in an attempt to maintain diastolic function at rest despite impaired relaxation in the diabetic fibrotic atrial myocardium. Our study addresses important aspects of the underlying mechanisms of diabetes-associated diastolic dysfunction, which is crucial to developing new therapeutic treatments.
Appendix
Available only for authorised users
Literature
1.
Jain A, Avendano G, Dharamsey S, Dasmahapatra A, Agarwal R, Reddi A, Regan T: Left ventricular diastolic function in hypertension and role of plasma glucose and insulin. Comparison with diabetic heart. Circulation. 1996, 93 (7): 1396-1402. 10.1161/01.CIR.93.7.1396.CrossRefPubMed
2.
From AM, Scott CG, Chen HH: The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol. 2010, 55 (4): 300-305. 10.1016/j.jacc.2009.12.003.CrossRefPubMed
3.
Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, Kitzman DW, Hopkins PN, Morgan D, Rao DC, Devereux RB: Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation. 2001, 103 (1): 102-107. 10.1161/01.CIR.103.1.102.CrossRefPubMed
4.
From AM, Scott CG, Chen HH: Changes in diastolic dysfunction in diabetes mellitus over time. Am J Cardiol. 2009, 103 (10): 1463-1466. 10.1016/j.amjcard.2009.01.358.PubMedCentralCrossRefPubMed
5.
Paulus WJ, van Ballegoij JJ: Treatment of heart failure with normal ejection fraction: an inconvenient truth!. J Am Coll Cardiol. 2010, 55 (6): 526-537. 10.1016/j.jacc.2009.06.067.CrossRefPubMed
6.
Zile MR, Baicu CF, Gaasch WH: Diastolic heart failure - abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004, 350 (19): 1953-1959. 10.1056/NEJMoa032566.CrossRefPubMed
7.
Regan TJ, Wu CF, Yeh CK, Oldewurtel HA, Haider B: Myocardial composition and function in diabetes. The effects of chronic insulin use. Circ Res. 1981, 49 (6): 1268-1277. 10.1161/01.RES.49.6.1268.CrossRefPubMed
8.
van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, Borbely A, van der Velden J, Stienen GJ, Laarman GJ, Niessen HW, Paulus WJ: Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008, 117 (1): 43-51. 10.1161/CIRCULATIONAHA.107.728550.CrossRefPubMed
9.
Pieske B, Maier LS, Schmidt-Schweda S: Sarcoplasmic reticulum Ca2+ load in human heart failure. Basic Res Cardiol. 2002, 97 (Suppl 1): I63-I71.PubMed
10.
Selby DE, Palmer BM, LeWinter MM, Meyer M: Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction. J Am Coll Cardiol. 2011, 58 (2): 147-154. 10.1016/j.jacc.2010.10.069.PubMedCentralCrossRefPubMed
11.
Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM: Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010, 3 (5): 588-595. 10.1161/CIRCHEARTFAILURE.109.930701.PubMedCentralCrossRefPubMed
12.
Zile MR, Gaasch WH: Abnormal calcium homeostasis: one mechanism in diastolic heart failure. J Am Coll Cardiol. 2011, 58 (2): 155-157. 10.1016/j.jacc.2010.10.068.CrossRefPubMed
13.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ: Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005, 18 (12): 1440-1463. 10.1016/j.echo.2005.10.005.CrossRefPubMed
14.
Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL: How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007, 28 (20): 2539-2550. 10.1093/eurheartj/ehm037.CrossRefPubMed
15.
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986, 57 (6): 450-458. 10.1016/0002-9149(86)90771-X.CrossRefPubMed
16.
Buakhamsri A, Popovic ZB, Lin J, Lim P, Greenberg NL, Borowski AG, Tang WH, Klein AL, Lever HM, Desai MY, Thomas JD: Impact of left ventricular volume/mass ratio on diastolic function. Eur Heart J. 2009, 30 (10): 1213-1221. 10.1093/eurheartj/ehp084.PubMedCentralCrossRefPubMed
17.
Lamberts RR, Van Rijen MH, Sipkema P, Fransen P, Sys SU, Westerhof N: Coronary perfusion and muscle lengthening increase cardiac contraction: different stretch-triggered mechanisms. Am J Physiol Heart Circ Physiol. 2002, 283 (4): H1515-H1522.CrossRefPubMed
18.
Biederman J, Yee J, Cortes P: Validation of internal control genes for gene expression analysis in diabetic glomerulosclerosis. Kidney Int. 2004, 66 (6): 2308-2314. 10.1111/j.1523-1755.2004.66016.x.CrossRefPubMed
19.
Fredersdorf S, Thumann C, Zimmermann WH, Vetter R, Graf T, Luchner A, Riegger GA, Schunkert H, Eschenhagen T, Weil J: Increased myocardial SERCA expression in early type 2 diabetes mellitus is insulin dependent: In vivo and in vitro data. Cardiovasc Diabetol. 2012, 11: 57-10.1186/1475-2840-11-57.PubMedCentralCrossRefPubMed
20.
Katare RG, Caporali A, Oikawa A, Meloni M, Emanueli C, Madeddu P: Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway. Circ Heart Fail. 2010, 3 (2): 294-305. 10.1161/CIRCHEARTFAILURE.109.903450.PubMedCentralCrossRefPubMed
21.
Schouten VJ, Allaart CP, Westerhof N: Effect of perfusion pressure on force of contraction in thin papillary muscles and trabeculae from rat heart. J Physiol. 1992, 451: 585-604.PubMedCentralCrossRefPubMed
22.
Borlaug BA, Redfield MM: Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011, 123 (18): 2006-2013. 10.1161/CIRCULATIONAHA.110.954388.PubMedCentralCrossRefPubMed
23.
Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE: Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology. 2002, 98 (1–2): 33-39.CrossRefPubMed
24.
Litwin SE, Raya TE, Anderson PG, Daugherty S, Goldman S: Abnormal cardiac function in the streptozotocin-diabetic rat. Changes in active and passive properties of the left ventricle. J Clin Invest. 1990, 86 (2): 481-488. 10.1172/JCI114734.PubMedCentralCrossRefPubMed
25.
Belke DD, Swanson EA, Dillmann WH: Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes. 2004, 53 (12): 3201-3208. 10.2337/diabetes.53.12.3201.CrossRefPubMed
26.
Reuter H, Gronke S, Adam C, Ribati M, Brabender J, Zobel C, Frank KF, Wippermann J, Schwinger RH, Brixius K, Muller-Ehmsen J: Sarcoplasmic Ca2+ release is prolonged in nonfailing myocardium of diabetic patients. Mol Cell Biochem. 2008, 308 (1–2): 141-149.CrossRefPubMed
27.
Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR: Altered myocardial force-frequency relation in human heart failure. Circulation. 1992, 85 (5): 1743-1750. 10.1161/01.CIR.85.5.1743.CrossRefPubMed
28.
von Lewinski D, Kockskamper J, Zhu D, Post H, Elgner A, Pieske B: Reduced stretch-induced force response in failing human myocardium caused by impaired Na+-contraction coupling. Circ Heart Fail. 2009, 2 (1): 47-55. 10.1161/CIRCHEARTFAILURE.108.794065.CrossRefPubMed
29.
Allen DG, Kentish JC: The cellular basis of the length-tension relation in cardiac muscle. J Mol Cell Cardiol. 1985, 17 (9): 821-840. 10.1016/S0022-2828(85)80097-3.CrossRefPubMed
30.
Weil J, Eschenhagen T, Hirt S, Magnussen O, Mittmann C, Remmers U, Scholz H: Preserved Frank-Starling mechanism in human end stage heart failure. Cardiovasc Res. 1998, 37 (2): 541-548. 10.1016/S0008-6363(97)00227-7.CrossRefPubMed
31.
Prasad A, Hastings JL, Shibata S, Popovic ZB, Arbab-Zadeh A, Bhella PS, Okazaki K, Fu Q, Berk M, Palmer D, Greenberg NL, Garcia MJ, Thomas JD, Levine BD: Characterization of static and dynamic left ventricular diastolic function in patients with heart failure with a preserved ejection fraction. Circ Heart Fail. 2010, 3 (5): 617-626. 10.1161/CIRCHEARTFAILURE.109.867044.PubMedCentralCrossRefPubMed
32.
Shibata S, Hastings JL, Prasad A, Fu Q, Bhella PS, Pacini E, Krainski F, Palmer MD, Zhang R, Levine BD: Congestive heart failure with preserved ejection fraction is associated with severely impaired dynamic Starling mechanism. J Appl Physiol. 2011, 110 (4): 964-971. 10.1152/japplphysiol.00826.2010.PubMedCentralCrossRefPubMed
33.
Altan VM, Arioglu E, Guner S, Ozcelikay AT: The influence of diabetes on cardiac beta-adrenoceptor subtypes. Heart Fail Rev. 2007, 12 (1): 58-65. 10.1007/s10741-007-9005-6.CrossRefPubMed
34.
Daniels A, van Bilsen M, Janssen BJ, Brouns AE, Cleutjens JP, Roemen TH, Schaart G, van der Velden J, van der Vusse GJ, van Nieuwenhoven FA: Impaired cardiac functional reserve in type 2 diabetic db/db mice is associated with metabolic, but not structural, remodelling. Acta Physiol. 2010, 200 (1): 11-22.
35.
Dincer UD, Bidasee KR, Guner S, Tay A, Ozcelikay AT, Altan VM: The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Diabetes. 2001, 50 (2): 455-461. 10.2337/diabetes.50.2.455.CrossRefPubMed
36.
Scognamiglio R, Avogaro A, Casara D, Crepaldi C, Marin M, Palisi M, Mingardi R, Erle G, Fasoli G, Dalla Volta S: Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1998, 31 (2): 404-412. 10.1016/S0735-1097(97)00516-0.CrossRefPubMed
37.
Dincer UD, Guner S, Tay A, Arioglu E, Tasdelen A, Aslamaci S, Bidasee KR: Decreased expression of beta1- and beta2-adrenoceptors in human diabetic atrial appendage. Cardiovasc Diabetol. 2003, 2: 6-10.1186/1475-2840-2-6.PubMedCentralCrossRefPubMed
38.
Zile MR, Kjellstrom B, Bennett T, Cho Y, Baicu CF, Aaron MF, Abraham WT, Bourge RC, Kueffer FJ: Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction. Circ Heart Fail. 2013, 6 (3): 508-516. 10.1161/CIRCHEARTFAILURE.112.000216.CrossRefPubMed
39.
Guner S, Arioglu E, Tay A, Tasdelen A, Aslamaci S, Bidasee KR, Dincer UD: Diabetes decreases mRNA levels of calcium-release channels in human atrial appendage. Mol Cell Biochem. 2004, 263 (1–2): 143-150.CrossRefPubMed
40.
Rosa CM, Xavier NP, Henrique Campos D, Fernandes AA, Cezar MD, Martinez PF, Cicogna AC, Gimenes C, Gimenes R, Okoshi MP, Okoshi K: Diabetes mellitus activates fetal gene program and intensifies cardiac remodeling and oxidative stress in aged spontaneously hypertensive rats. Cardiovasc Diabetol. 2013, 12 (1): 152-10.1186/1475-2840-12-152.PubMedCentralCrossRefPubMed
41.
Li S, Li X, Li YL, Shao CH, Bidasee KR, Rozanski GJ: Insulin regulation of glutathione and contractile phenotype in diabetic rat ventricular myocytes. Am J Physiol Heart Circ Physiol. 2007, 292 (3): H1619-H1629.CrossRefPubMed
42.
Mourmoura E, Vial G, Laillet B, Rigaudiere JP, Hininger-Favier I, Dubouchaud H, Morio B, Demaison L: Preserved endothelium-dependent dilatation of the coronary microvasculature at the early phase of diabetes mellitus despite the increased oxidative stress and depressed cardiac mechanical function ex vivo. Cardiovasc Diabetol. 2013, 12: 49-10.1186/1475-2840-12-49.PubMedCentralCrossRefPubMed
43.
Balderas-Villalobos J, Molina-Munoz T, Mailloux-Salinas P, Bravo G, Carvajal K, Gomez-Viquez NL: Oxidative stress in cardiomyocytes contributes to decreased SERCA2a activity in rats with metabolic syndrome. Am J Physiol Heart Circ Physiol. 2013, 305 (9): H1344-H1353. 10.1152/ajpheart.00211.2013.CrossRefPubMed
44.
Malhotra A, Reich D, Reich D, Nakouzi A, Sanghi V, Geenen DL, Buttrick PM: Experimental diabetes is associated with functional activation of protein kinase C epsilon and phosphorylation of troponin I in the heart, which are prevented by angiotensin II receptor blockade. Circ Res. 1997, 81 (6): 1027-1033. 10.1161/01.RES.81.6.1027.CrossRefPubMed
45.
Jweied EE, McKinney RD, Walker LA, Brodsky I, Geha AS, Massad MG, Buttrick PM, de Tombe PP: Depressed cardiac myofilament function in human diabetes mellitus. Am J Physiol Heart Circ Physiol. 2005, 289 (6): H2478-H2483. 10.1152/ajpheart.00638.2005.CrossRefPubMed
46.
Takeda N, Nakamura I, Hatanaka T, Ohkubo T, Nagano M: Myocardial mechanical and myosin isoenzyme alterations in streptozotocin-diabetic rats. Jpn Heart J. 1988, 29 (4): 455-463. 10.1536/ihj.29.455.CrossRefPubMed
47.
48.
Miyata S, Minobe W, Bristow MR, Leinwand LA: Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res. 2000, 86 (4): 386-390. 10.1161/01.RES.86.4.386.CrossRefPubMed
49.
van Hoeven KH, Factor SM: A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation. 1990, 82 (3): 848-855. 10.1161/01.CIR.82.3.848.CrossRefPubMed
50.
Asbun J, Villarreal FJ: The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol. 2006, 47 (4): 693-700. 10.1016/j.jacc.2005.09.050.CrossRefPubMed
51.
Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, Hanssen KF: Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care. 1999, 22 (7): 1186-1190. 10.2337/diacare.22.7.1186.CrossRefPubMed
52.
Borbely A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, Paulus WJ: Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005, 111 (6): 774-781. 10.1161/01.CIR.0000155257.33485.6D.CrossRefPubMed
53.
Falcao-Pires I, Hamdani N, Borbely A, Gavina C, Schalkwijk CG, van der Velden J, van Heerebeek L, Stienen GJ, Niessen HW, Leite-Moreira AF, Paulus WJ: Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation. 2011, 124 (10): 1151-1159. 10.1161/CIRCULATIONAHA.111.025270.CrossRefPubMed
54.
Hamdani N, Franssen C, Lourenco A, Falcao-Pires I, Fontoura D, Leite S, Plettig L, Lopez B, Ottenheijm CA, Becher PM, Gonzalez A, Tschope C, Diez J, Linke WA, Leite-Moreira AF, Paulus WJ: Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ Heart Fail. 2013, 6 (6): 1239-1249. 10.1161/CIRCHEARTFAILURE.113.000539.CrossRefPubMed
55.
Kruger M, Babicz K, von Frieling-Salewsky M, Linke WA: Insulin signaling regulates cardiac titin properties in heart development and diabetic cardiomyopathy. J Mol Cell Cardiol. 2010, 48 (5): 910-916. 10.1016/j.yjmcc.2010.02.012.CrossRefPubMed
56.
Bupha-Intr T, Oo YW, Wattanapermpool J: Increased myocardial stiffness with maintenance of length-dependent calcium activation by female sex hormones in diabetic rats. Am J Physiol Heart Circ Physiol. 2011, 300 (5): H1661-H1668. 10.1152/ajpheart.00411.2010.CrossRefPubMed
57.
Zeina AR, Odeh M, Rosenschein U, Zaid G, Barmeir E: Coronary artery disease among asymptomatic diabetic and nondiabetic patients undergoing coronary computed tomography angiography. Coronary artery disease. 2008, 19 (1): 37-41. 10.1097/MCA.0b013e3282f2f19e.CrossRefPubMed
58.
Lewis EF, Solomon SD, Jablonski KA, Rice MM, Clemenza F, Hsia J, Maggioni AP, Zabalgoitia M, Huynh T, Cuddy TE, Gersh BJ, Rouleau J, Braunwald E, Pfeffer MA: Predictors of heart failure in patients with stable coronary artery disease: a PEACE study. Circ Heart Fail. 2009, 2 (3): 209-216. 10.1161/CIRCHEARTFAILURE.108.820696.PubMedCentralCrossRefPubMed
59.
Bootman MD, Higazi DR, Coombes S, Roderick HL: Calcium signalling during excitation-contraction coupling in mammalian atrial myocytes. Journal of cell science. 2006, 119 (Pt 19): 3915-3925.CrossRefPubMed
60.
Luss I, Boknik P, Jones LR, Kirchhefer U, Knapp J, Linck B, Luss H, Meissner A, Muller FU, Schmitz W, Vahlensieck U, Neumann J: Expression of cardiac calcium regulatory proteins in atrium v ventricle in different species. J Mol Cell Cardiol. 1999, 31 (6): 1299-1314. 10.1006/jmcc.1999.0962.CrossRefPubMed
Metadata
Title
Impaired relaxation despite upregulated calcium-handling protein atrial myocardium from type 2 diabetic patients with preserved ejection fraction
Authors
Regis R Lamberts
Shivanjali J Lingam
Heng-Yu Wang
Ilse AE Bollen
Gillian Hughes
Ivor F Galvin
Richard W Bunton
Andrew Bahn
Rajesh Katare
J Chris Baldi
Michael JA Williams
Pankaj Saxena
Sean Coffey
Peter P Jones
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2014
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-13-72

Other articles of this Issue 1/2014

Cardiovascular Diabetology 1/2014 Go to the issue

Review

Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor

Original investigation

Nestin downregulation in rat vascular smooth muscle cells represents an early marker of vascular disease in experimental type I diabetes

Original investigation

Acute insulin resistance in ST-segment elevation myocardial infarction in non-diabetic patients is associated with incomplete myocardial reperfusion and impaired coronary microcirculatory function

Original investigation

Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway

Original investigation

Analysis of common and coding variants with cardiovascular disease in the diabetes heart study

Original investigation

Vaspin inhibits cytokine-induced nuclear factor-kappa B activation and adhesion molecule expression via AMP-activated protein kinase activation in vascular endothelial cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits